Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis

CONCLUSIONS: We found moderate- to high-certainty evidence that donepezil 5 mg, donepezil 10 mg, and galantamine have a slight beneficial effect on cognition in people with VCI, although the size of the change is unlikely to be clinically important. Donepezil 10 mg and galantamine 16 to 24 mg are probably associated with more adverse events than placebo. The evidence for rivastigmine was less certain. The data suggest that donepezil 10 mg has the greatest effect on cognition, but at the cost of adverse effects. The effect is modest, but in the absence of any other treatments, people living with VCI may still wish to consider the use of these agents. Further research into rivastigmine is needed, including the use of transdermal patches.PMID:33704781 | DOI:10.1002/14651858.CD013306.pub2

Source: Cochrane Database of Systematic Reviews - March 11, 2021 Category: General Medicine Authors: Ceri E Battle Azmil H Abdul-Rahim Susan D Shenkin Jonathan Hewitt Terry J Quinn Source Type: research